Detalhe da pesquisa
1.
Long-term Remissions Following CD20-directed Chimeric Antigen Receptor Adoptive T cell Therapy.
Blood Cancer Discov;
2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38747505
2.
HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Blood;
2024 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38683966
3.
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Blood Adv;
8(4): 895-898, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38197942
4.
Cytomegalovirus (CMV) Reactivation and CMV-Specific Cell-Mediated Immunity After Chimeric Antigen Receptor T-Cell Therapy.
Clin Infect Dis;
78(4): 1022-1032, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37975819
5.
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Blood Adv;
8(2): 453-467, 2024 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37903325
6.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood;
143(5): 404-416, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890149
7.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Blood;
143(6): 496-506, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879047
8.
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Blood Adv;
7(22): 6990-7005, 2023 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774014
9.
Bortezomib and Vorinostat Therapy as Maintenance Therapy Post Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
Acta Haematol;
2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708877
10.
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Lancet Oncol;
24(7): 811-822, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414012
11.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet;
402(10402): 641-654, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295445
12.
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther;
29(7): 430-437, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031746
13.
Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy.
Am J Transplant;
23(3): 416-422, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748802
14.
Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor-modified T-cell therapy.
Blood Adv;
7(9): 1849-1853, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094846
15.
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
J Cell Mol Med;
26(24): 5976-5983, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36453136
16.
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
Leuk Lymphoma;
63(12): 2918-2922, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35811554
17.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet;
399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
18.
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Blood;
139(26): 3722-3731, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35439295
19.
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.
Exp Hematol Oncol;
11(1): 17, 2022 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337365
20.
Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma.
Pharmacoecon Open;
6(3): 367-376, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35129829